Molecular structure of Ranolazine, CAS Number: 95635-55-5
Ranolazine (CAS 95635-55-5)
See product citations (3)
Application:
Ranolazine is an anti-ischemic agent which inhibits late sodium currents
CAS Number:
95635-55-5
Purity:
≥98%
Molecular Weight:
427.54
Molecular Formula:
C24H33N3O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ranolazine is an anti-ischemic compound, which inhibits late sodium current that results in a reduction of Na+ dependent Ca2+ overload. Studies indicate that ATP production is shifted towards glucose oxidation by Ranolazine. This is due to the fact that more oxygen is required to phosphorylate the same amount of ATP during fatty acid oxidation than carbohydrate oxidation. These studies indicate that Ranolazine also inhibits oxygen consumption and ketogenesis by fatty acids in liver cells.
Ranolazine (CAS 95635-55-5) References
- The use of ranolazine in cardiovascular disease. | Schofield, RS. and Hill, JA. 2002. Expert Opin Investig Drugs. 11: 117-23. PMID: 11772326
- Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. | Chaitman, BR., et al. 2004. J Am Coll Cardiol. 43: 1375-82. PMID: 15093870
- Effects of ranolazine on fatty acid transformation in the isolated perfused rat liver. | Mito, MS., et al. 2010. Mol Cell Biochem. 345: 35-44. PMID: 20680408
- [Ranolazine--an additional anti-anginal drug]. | Michels, G., et al. 2010. Dtsch Med Wochenschr. 135: 2037-40. PMID: 20925013
- Ranolazine and its Antiarrhythmic Actions. | Polytarchou, K. and Manolis, AS. 2015. Cardiovasc Hematol Agents Med Chem. 13: 31-9. PMID: 26245658
- Ranolazine and Its Effects on Hemoglobin A1C. | Greiner, L., et al. 2016. Ann Pharmacother. 50: 410-5. PMID: 26917816
- Ranolazine: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias. | Shenasa, M., et al. 2016. Card Electrophysiol Clin. 8: 467-79. PMID: 27261835
- Ranolazine Therapy in Cardiac Arrhythmias. | Pulford, BR. and Kluger, J. 2016. Pacing Clin Electrophysiol. 39: 1006-15. PMID: 27358212
- Ranolazine for stable angina pectoris. | Salazar, CA., et al. 2017. Cochrane Database Syst Rev. 2: CD011747. PMID: 28178363
- Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model. | Cassano, V., et al. 2020. Nutrients. 12: PMID: 32023991
- Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction. | Sharp, RP., et al. 2021. Am J Cardiovasc Drugs. 21: 513-521. PMID: 33438139
- Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina. | Tamargo, J. and Lopez-Sendon, J. 2022. Future Cardiol. 18: 235-251. PMID: 34841884
- Role of ranolazine in heart failure: From cellular to clinic perspective. | Kaplan, A., et al. 2022. Eur J Pharmacol. 919: 174787. PMID: 35114190
- Ranolazine: a novel metabolic modulator for the treatment of angina. | McCormack, JG., et al. 1998. Gen Pharmacol. 30: 639-45. PMID: 9559312
Inhibitor of:
1700095B22Rik, ACAA1, Acaa1b, ACAD-10, ACAD-11, ACAD-12, ACADVL, ACSL6, ACSM4, Carnitine Acetyltransferase, CPTI-L, CPTII, CROT, Dbil5, ECH1, ECHDC2, ECHDC3, ECHS1, gp210, HADHSC, HCN1, HCN4, Influenza A ns2, karyopherin α1, MCAD, Na+ CP type Iβ, Na+ CP type IVα, Na+ CP type VIIα, NaS-1, NCX3, NHEDC1, NIPA, NTF2, Olr20, Olr409, PCP-4, Ran BP-2, SCNM1, sodium channel type II, sodium channel type IV, and VRL-1.Activator of:
Na+ CP type IVα, Na+ CP type Xα, and sodium channel type II.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ranolazine, 1 g | sc-212769 | 1 g | $109.00 |